Semaglutide – Dnyan pravah news

Mounjaro hits shelves in India: How Eli Lilly’s anti-diabetes drug compares with Ozempic — price, side effects and more

adminMarch 20, 2025012 mins

Eli Lilly has introduced Mounjaro (tirzepatide), a weekly injectable medication for obesity and type 2 diabetes, in India after receiving approval from the Central Drugs Standard Control Organisation (CDSCO). Mounjaro is notable for its dual-action mechanism, targeting both GLP-1 and GIP receptors, which enhances its effectiveness in managing blood sugar levels. While Ozempic is often…

Is obesity a disease? | Mint

adminMarch 19, 202507 mins

For years there has been a push to recognise obesity as a disease in its own right, and therefore something that needs to be treated in and of itself, rather than just as a risk factor for other things, such as diabetes, heart disease, strokes and some cancers. And there is indeed much evidence that…

Ozempic maker Novo Nordisk prepared to enter India despite patent expiry, generic competition

adminMarch 6, 202506 mins

Danish drugmaker Novo Nordisk is prepared to enter the Indian market and other markets with its blockbuster drug Ozempic, despite losing patent exclusivity early next year. “Even as we face patent expiration for Semaglutide, we’ll probably still launch the product in markets and [drive] volume growth, and to do that we need to have a…